- NEWS AND VIEWS
Parkinson’s disease grafts benefit from well-timed growth factor
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 582, 39-40 (2020)
doi: https://doi.org/10.1038/d41586-020-01486-3
References
Barker, R. A., Drouin-Ouellet, J. & Parmar, M. Nature Rev. Neurol. 11, 492–503 (2015).
Barker, R. A., Parmar, M., Studer, L. & Takahashi, J. Cell Stem Cell 21, 569–573 (2017).
Tabar, V. & Studer, L. Nature Rev. Genet. 15, 82–92 (2014).
Gantner, C. W. et al. Cell Stem Cell 26, 511–526 (2020).
Kirik, D., Cederfjäll, E., Halliday, G. & Petersén, A. Neurobiol. Dis. 97, 179–188 (2017).
Rosenblad, C., Martinez-Serrano, A. & Björklund, A. Neuroscience 75, 979–985 (1996).
Kikuchi, T. et al. Nature 548, 592–596 (2017).
Deuse, T. et al. Nature Biotechnol. 37, 252–258 (2019).
Gornalusse, G. G. et al. Nature Biotechnol. 35, 765–772 (2017).
Luk, K. C. et al. Science 338, 949–953 (2012).
Steinbeck, J. A. & Studer, L. Neuron 86, 187–206 (2015).
Competing Interests
L.S. is a scientific founder and paid consultant of BlueRock Therapeutics and an inventor on patents related to the differentiation of dopamine neurons from pluripotent stem cells. V.T. is a founding investigator and paid consultant of BlueRock Therapeutics.